Jim Cramer: Joby Is 'Losing Too Much Money'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a “very interesting spec.”Piper Sandler analyst David Amsellem, on Nov. 7, maintained Aquestive Therapeutics with an Overweight rating and raised the price target from $5 to $8.Amphenol Corporation (NYSE:APH) is such a “great” stock, Cramer said. “You want to stay in that cable play.”Supporting his view, Amphenol reported better-than-expected fiscal third-quarter 2025 results on Oct. 22. Quarterly sales incr ...